These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 9813922

  • 41. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
    Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, André FE.
    Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057
    [Abstract] [Full Text] [Related]

  • 42. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
    Nakayama T, Urano T, Osano M, Nakagawa M, Maehara N, Sasaki K, Yamamura AM, Makino S.
    Microbiol Immunol; 1990 Nov; 34(6):497-508. PubMed ID: 2120551
    [Abstract] [Full Text] [Related]

  • 43. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M, Berger R, Just V.
    Dev Biol Stand; 1986 Nov; 65():85-8. PubMed ID: 3030863
    [Abstract] [Full Text] [Related]

  • 44. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E, Tischer A.
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [Abstract] [Full Text] [Related]

  • 45. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts.
    Davidkin I, Valle M.
    Vaccine; 1998 Dec; 16(20):2052-7. PubMed ID: 9796064
    [Abstract] [Full Text] [Related]

  • 46. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response.
    Halperin SA, McGrath P, Smith B, Houston T.
    J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878
    [Abstract] [Full Text] [Related]

  • 47. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F, Manzionna MM, De Mattia D, Amendola F, Di Bitonto G.
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [Abstract] [Full Text] [Related]

  • 48. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months.
    Böttiger M.
    Vaccine; 1995 Dec; 13(18):1759-62. PubMed ID: 8701590
    [Abstract] [Full Text] [Related]

  • 49. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [Abstract] [Full Text] [Related]

  • 50. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months.
    Forleo-Neto E, Carvalho ES, Fuentes IC, Precivale MS, Forleo LH, Farhat CK.
    Vaccine; 1997 Dec; 15(17-18):1898-901. PubMed ID: 9413099
    [Abstract] [Full Text] [Related]

  • 51. Duration of the immune response to MMR vaccine in children of two age-different groups.
    Li Volti S, Giammanco-Bilancia G, Grassi M, Garozzo R, Gluck R, Giammanco G.
    Eur J Epidemiol; 1993 May; 9(3):311-4. PubMed ID: 8405317
    [Abstract] [Full Text] [Related]

  • 52. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR.
    Proc Soc Exp Biol Med; 1980 Nov; 165(2):260-3. PubMed ID: 7443713
    [No Abstract] [Full Text] [Related]

  • 53. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC, Burgess MA, O'Brien ED.
    Commun Dis Intell; 1998 Aug 06; 22(8):159. PubMed ID: 9735551
    [No Abstract] [Full Text] [Related]

  • 54. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
    Klinge J, Lugauer S, Korn K, Heininger U, Stehr K.
    Vaccine; 2000 Jul 15; 18(27):3134-40. PubMed ID: 10856793
    [Abstract] [Full Text] [Related]

  • 55. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura.
    Pool V, Chen R, Rhodes P.
    Pediatr Infect Dis J; 1997 Apr 15; 16(4):423-4. PubMed ID: 9109153
    [No Abstract] [Full Text] [Related]

  • 56. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.
    Boulianne N, De Serres G, Ratnam S, Ward BJ, Joly JR, Duval B.
    Vaccine; 1995 Nov 15; 13(16):1611-6. PubMed ID: 8578850
    [Abstract] [Full Text] [Related]

  • 57. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
    Senterre J.
    Rev Med Liege; 1999 Feb 15; 54(2):122-4. PubMed ID: 10221066
    [Abstract] [Full Text] [Related]

  • 58. Combined vaccine against measles, mumps, rubella, and varicella.
    Brunell PA, Novelli VM, Lipton SV, Pollock B.
    Pediatrics; 1988 Jun 15; 81(6):779-84. PubMed ID: 2835743
    [Abstract] [Full Text] [Related]

  • 59. An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants.
    Dunlop JM, RaiChoudhury K, Roberts JS, Bryett KA.
    Public Health; 1989 Sep 15; 103(5):331-5. PubMed ID: 2798746
    [Abstract] [Full Text] [Related]

  • 60. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
    Beck M, Smerdel S, Dedić I, Delimar N, Rajninger-Miholic M, Juzbasić M, Manhalter T, Vlatković R, Borcić B, Mihajić Z.
    Dev Biol Stand; 1986 Sep 15; 65():95-100. PubMed ID: 3556780
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.